Placebo News and Research

RSS

Regeneron's COVID-19 antibody-drug cocktail treats SARS-CoV-2 virus in animals

Now, Regeneron Pharmaceuticals says its COVID-19 antibody-drug cocktail under development prevented and treated the disease in monkeys and hamsters, showing promise that it may work in humans.

5 Aug 2020

ACTG initiates novel clinical trial to evaluate multiple therapeutics for COVID-19

The AIDS Clinical Trials Group, the world's largest and longest established HIV research network, today announced the initiation of the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial, which will be conducted by the ACTG.

4 Aug 2020

NIH trial to evaluate potential new therapeutics for mild, moderate COVID-19

A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease.

4 Aug 2020

Regeneron antibody cocktail shows promise as potential COVID-19 treatment

Researchers in the U.S. have shown both preventive and treatment effects of an antibody cocktail in animal models of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - the agent that causes coronavirus disease 2019 (COVID-19).

4 Aug 2020

Clinical trial to test safety, efficacy of antibody treatment in hospitalized COVID-19 patients

Patients admitted with COVID-19 at select hospitals may now volunteer to enroll in a clinical trial to test the safety and efficacy of a potential new treatment for the disease.

4 Aug 2020

Heart cell treatment can benefit patients, shows study

More than three years after a clinical trial was prematurely ended for failing to show progress in healing heart attack scars, a prominent peer-reviewed journal is publishing some surprising results showing that the heart cell treatment does benefit patients.

4 Aug 2020

Targeting LDL cholesterol to reduce heart disease risk now questioned

For many years, health experts have warned that high levels of bad cholesterol or low-density lipoprotein (LDL) are critical drivers for the development of cardiovascular disease. Now, a new study claims that decades of research have failed to show benefit of targeting the bad cholesterol to reduce the risk of cardiovascular disease.

4 Aug 2020

Darolutamide shows indication of considerable added benefit in prostate cancer

Up to now, adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) at high risk of developing metastatic disease usually continued their conventional androgen deprivation therapy (ADT) while the cancer was observed for the occurrence of metastases (so-called watchful waiting).

3 Aug 2020

Asthma drugs improve performance in healthy non-asthmatic subjects

Popular asthma control drugs β2-agonists such as Albuterol, Formoterol, Terbutaline, etc. that are used as inhalers by millions of asthmatics around the world could have power and stamina enhancing properties in sportspersons, finds a new study.

3 Aug 2020

Maternal vaccination could protect infants against RSV illness

Immunizing pregnant women with a potential vaccine against RSV could prevent the most common cause of pneumonia in their babies.

3 Aug 2020

The race to a coronavirus vaccine

As the number of coronavirus disease (COVID-19) cases skyrocket to a staggering 18 million, the race to attain vaccine approval is on. More than a hundred candidate vaccines are being developed and tested to prevent infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Now, many vaccine candidates are undergoing human stage 2 and 3 trials to prove their efficacy and safety.

2 Aug 2020

FDA approves CBD oral solution for treatment of seizures related to tuberous sclerosis complex

Today, the U.S. Food and Drug Administration approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older.

31 Jul 2020

Study examines glucocorticoid tapering in rheumatoid arthritis

Is the long-term use of glucocorticoids essential in people with chronic inflammatory diseases such as rheumatoid arthritis, or can early discontinuation prevent characteristic side effects?

31 Jul 2020

Novel vaccine candidate robustly protects non-human primates against SARS-CoV-2

The development of a safe and effective vaccine will likely be required to end the COVID-19 pandemic. A group of scientists, led by Beth Israel Deaconess Medical Center immunologist Dan H. Barouch, MD, PhD, now report that a leading candidate COVID-19 vaccine developed at BIDMC in collaboration with Johnson & Johnson raised neutralizing antibodies and robustly protected non-human primates against SARS-CoV-2, the virus that causes COVID-19.

30 Jul 2020

Pimavanserin reduced psychotic symptoms in people with dementia in phase 3 study

A large-scale trial has found a treatment with pimavanserin substantially reduced psychotic symptoms and reduced risk of relapse of those symptoms compared to placebo in people with dementia, a condition for which no treatments are currently licensed.

29 Jul 2020

Public health experts fear a hasty FDA signoff on vaccine

The vaccine trial that Vice President Mike Pence kicked off in Miami on Monday gives the United States the tiniest chance of being ready to vaccinate millions of Americans just before Election Day.

29 Jul 2020

Researchers launch randomized, placebo-controlled clinical trial of pulmozyme in COVID-19 patients

Researchers at Boston Children's Hospital and Brigham and Women's Hospital have launched a randomized, placebo-controlled clinical trial of dornase alfa (Pulmozyme) in patients with severe COVID-19 pneumonia and respiratory failure requiring mechanical ventilation.

29 Jul 2020

Experimental vaccine rapidly controls coronavirus in the upper and lower airways of nonhuman primates

Two doses of an experimental vaccine to prevent coronavirus disease 2019 (COVID-19) induced robust immune responses and rapidly controlled the coronavirus in the upper and lower airways of rhesus macaques exposed to SARS-CoV-2, report scientists from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. SARS-CoV-2 is the virus that causes COVID-19.

28 Jul 2020

Moderna coronavirus vaccine candidate moves to phase 3 with 30,000 participants

The world’s most significant coronavirus disease (COVID-19) vaccine study is underway in the United States, with a planned 30,000 volunteers. The phase 3 clinical trial aims to examine the efficacy and safety of the candidate vaccine developed by the National Institutes of Health and Moderna Inc.

28 Jul 2020

GW to participate in a clinical trial for investigational COVID-19 vaccine

The George Washington University today announced that it will participate in a clinical trial for an investigational COVID-19 vaccine.

27 Jul 2020

Placebo News and Research

Regeneron's COVID-19 antibody-drug cocktail treats SARS-CoV-2 virus in animals

ACTG initiates novel clinical trial to evaluate multiple therapeutics for COVID-19

NIH trial to evaluate potential new therapeutics for mild, moderate COVID-19

Regeneron antibody cocktail shows promise as potential COVID-19 treatment

Clinical trial to test safety, efficacy of antibody treatment in hospitalized COVID-19 patients

Heart cell treatment can benefit patients, shows study

Targeting LDL cholesterol to reduce heart disease risk now questioned

Darolutamide shows indication of considerable added benefit in prostate cancer

Asthma drugs improve performance in healthy non-asthmatic subjects

Maternal vaccination could protect infants against RSV illness

The race to a coronavirus vaccine

FDA approves CBD oral solution for treatment of seizures related to tuberous sclerosis complex

Study examines glucocorticoid tapering in rheumatoid arthritis

Novel vaccine candidate robustly protects non-human primates against SARS-CoV-2

Pimavanserin reduced psychotic symptoms in people with dementia in phase 3 study

Public health experts fear a hasty FDA signoff on vaccine

Researchers launch randomized, placebo-controlled clinical trial of pulmozyme in COVID-19 patients

Experimental vaccine rapidly controls coronavirus in the upper and lower airways of nonhuman primates

Moderna coronavirus vaccine candidate moves to phase 3 with 30,000 participants

GW to participate in a clinical trial for investigational COVID-19 vaccine

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News